Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
February 22, 2018BioTime Appoints Cavan Redmond to Its Board of Directors
Former CEO of WebMD, former General Manager of Wyeth Biopharma and Group President of Pfizer 30 Years of Executive Management and Corporate Strategy Experience in Biopharma ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 22, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, announced the appointment of Cavan Redm... 
Printer Friendly Version
February 15, 2018Data from BioTime's OpRegen® and Vision Restoration Programs to Be Presented at ARVO 2018
OpRegen® is in a Phase I/IIa clinical trial for dry-AMD Vision Restoration – Our 3-Dimensional Retinal Tissue Program ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 15, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that two abstracts have been accepted and will be presented at the upcoming Association f... 
Printer Friendly Version
February 07, 2018BioTime to Participate at the BIO CEO and Investor Conference in New York, February 12th and 13th 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 7, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty, Co-Chief Executive Officer of BioTime, will participate in the BIO CEO and Investor Conference, on February 12th and 13th 2018, at the New York Marriott Marquis. The BIO CEO and Investor Conference is one ... 
Printer Friendly Version
January 29, 2018Renevia® Data From the Successful Pivotal Trial to Be Presented at the IMCAS Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 29, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that detailed data from the successful pivotal trial of Renevia® in Europe will be presented at the International Master Course on Aging Science (IMCAS) conference on February 3, 2018. The Renevia® data will be presented by primar... 
Printer Friendly Version
January 23, 2018BioTime to Present at the Noble Capital Markets 14th Annual Institutional Investor Conference in Fort Lauderdale, January 29, 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 23, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer, will be presenting at the Noble Capital Markets 14th Annual Investor Conference on Monday, January 29, 2018 at 4:00pm ET, at the W Hotel Fort Lauderdale. A webcast of ... 
Printer Friendly Version
January 22, 2018BioTime Announces Clinical and Corporate Milestone Targets for 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 22, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced its 2018 clinical and corporate milestone targets. BioTime will continue to focus on the core pillars of its stated strategy of Clinical Progress, Simplification and Unlocking Value for BioTime Shareholders. ... 
Printer Friendly Version
January 18, 2018AgeX CEO Michael D. West to Present in Plenary Session at The World Stem Cell Summit on “Stem Cell Innovations That Will Change the World”
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 18, 2018-- AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), today announced that AgeX will present in a Plenary session, “Stem Cell Innovations That Will Change the World – Part 2,” at the World Stem Cell Summit (WSCS) on Thursday, January 25, 2018 at the Hyatt Regency Miami. AgeX CEO Michael D. West, Ph.D. will provide an update on AgeX’s core programs in cardiovascular and... 
Printer Friendly Version
January 17, 2018BioTime Announces Issuance of 41 New Patents to Expand and Bolster Its Patent Estate
BioTime expands and strengthens patent estate covering OpRegen® through 2031 Expanded and strengthened patent coverage of pluripotent cell technology ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 17, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced the issuance of 41 new patents over th... 
Printer Friendly Version
January 05, 2018AgeX Therapeutics to Present at Biotech Showcase Annual Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 5, 2018-- AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), today announced that it will present at Biotech Showcase, January 8-10, 2018 at the Hilton San Francisco Union Square. Michael D. West, Ph.D., Chief Executive Officer, will present at the conference as follows: Date: Tuesday, January 9 Time: 2:30 PM PST Track: Yosemite-B (Ballroom Level) Venue: Hil... 
Printer Friendly Version
January 02, 2018AgeX Therapeutics Identifies Genes Implicated in Tissue Regeneration and Cancer
- Published in the peer-reviewed journal Oncotarget – - Potential applications in scarless tissue regeneration, cancer, and aging - ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 2, 2018-- AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE American: BTX), today announced a newly-published peer-reviewed study that reveals genes implicated in tissue regeneration, cancer, and aging. The study, by scientists at AgeX and ... 
Printer Friendly Version